Targeting CD39 with a first-in-class inhibitory antibody prevents ATP processing and increases T-cell activation

: Lerner AG, Kovalenko M, Welch M, Dela Cruz T, Jones J, Wong C, Spatola B, Eberhardt M, Wong A, Fung W, Lagpacan L, Losenkova K, Yegutkin G, Soros V, Corbin J, Beers C, Moesta AK, Moesta AK

Publisher: AMER ASSOC CANCER RESEARCH

: 2019

: Cancer Research

: CANCER RESEARCH

: CANCER RES

: 79

: 13 Suppl.

: 2

: 0008-5472

DOI: https://doi.org/10.1158/1538-7445.AM2019-5012(external)